146 related articles for article (PubMed ID: 711853)
1. Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.
Chung KS; Madar DA; Goldsmith JC; Kingdon HS; Roberts HR
J Clin Invest; 1978 Nov; 62(5):1078-85. PubMed ID: 711853
[TBL] [Abstract][Full Text] [Related]
2. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
de la Salle C; Charmantier JL; Ravanat C; Ohlmann P; Hartmann ML; Schuhler S; Bischoff R; Ebel C; Roecklin D; Balland A
Nouv Rev Fr Hematol (1978); 1993; 35(5):473-80. PubMed ID: 8295821
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
[TBL] [Abstract][Full Text] [Related]
4. Activation of normal and abnormal human factor IX with trypsin.
Monroe DM; Noyes CM; Straight DL; Roberts HR; Griffith MJ
Arch Biochem Biophys; 1985 May; 238(2):490-6. PubMed ID: 3873217
[TBL] [Abstract][Full Text] [Related]
5. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.
Thompson AR
J Clin Invest; 1977 May; 59(5):900-10. PubMed ID: 856873
[TBL] [Abstract][Full Text] [Related]
6. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
[TBL] [Abstract][Full Text] [Related]
7. Characterization of gamma-carboxyglutamic acid residue 21 of human factor IX.
Wolberg AS; Li L; Cheung WF; Hamaguchi N; Pedersen LG; Stafford DW
Biochemistry; 1996 Aug; 35(32):10321-7. PubMed ID: 8756687
[TBL] [Abstract][Full Text] [Related]
8. Structure and function of factor IX: defects in haemophilia B.
McGraw RA; Davis LM; Lundblad RL; Stafford DW; Roberts HR
Clin Haematol; 1985 Jun; 14(2):359-83. PubMed ID: 3899439
[TBL] [Abstract][Full Text] [Related]
9. Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor.
Osterud B; Kasper CK; Lavine KK; Prodanos C; Rapaport SI
Thromb Haemost; 1981 Feb; 45(1):55-9. PubMed ID: 7245126
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of factor IX Chapel Hill: comparison to normal human factor IX.
Chung KS; Goldsmith JC; Roberts HR
Bibl Haematol; 1977; 44():68-74. PubMed ID: 617785
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
Griffith MJ; Breitkreutz L; Trapp H; Briet E; Noyes CM; Lundblad RL; Roberts HR
J Clin Invest; 1985 Jan; 75(1):4-10. PubMed ID: 3871202
[TBL] [Abstract][Full Text] [Related]
12. Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase.
Stanley TB; Wu SM; Houben RJ; Mutucumarana VP; Stafford DW
Biochemistry; 1998 Sep; 37(38):13262-8. PubMed ID: 9748333
[TBL] [Abstract][Full Text] [Related]
13. Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
Bertina RM; van der Linden IK
Thromb Haemost; 1982 Apr; 47(2):136-40. PubMed ID: 7101232
[TBL] [Abstract][Full Text] [Related]
14. In vitro mutagenesis study of two critical glutamic acids in the calcium binding loop of the factor IX heavy chain.
Hamaguchi N; Stafford D
Thromb Haemost; 1994 Dec; 72(6):856-61. PubMed ID: 7740454
[TBL] [Abstract][Full Text] [Related]
15. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
Bertina RM; Van Der Linden IK
J Lab Clin Med; 1982 Nov; 100(5):695-704. PubMed ID: 7130828
[TBL] [Abstract][Full Text] [Related]
16. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
Noyes CM; Griffith MJ; Roberts HR; Lundblad RL
Proc Natl Acad Sci U S A; 1983 Jul; 80(14):4200-2. PubMed ID: 6603618
[TBL] [Abstract][Full Text] [Related]
17. Comparison of lipid binding and kinetic properties of normal, variant, and gamma-carboxyglutamic acid modified human factor IX and factor IXa.
Jones ME; Griffith MJ; Monroe DM; Roberts HR; Lentz BR
Biochemistry; 1985 Dec; 24(27):8064-9. PubMed ID: 3879187
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis.
Taylor SA; Duffin J; Cameron C; Teitel J; Garvey B; Lillicrap DP
Thromb Haemost; 1992 Jan; 67(1):63-5. PubMed ID: 1615485
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of a cDNA coding for human factor IX.
Kurachi K; Davie EW
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6461-4. PubMed ID: 6959130
[TBL] [Abstract][Full Text] [Related]
20. Two mutations of the factor IX gene including a donor splice consensus deletion and a point mutation in a Dutch patient with severe hemophilia B.
Poort SR; Briët E; Bertina RM; Reitsma PH
Thromb Haemost; 1990 Nov; 64(3):379-84. PubMed ID: 2096489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
